Xoma Earns $9M As FDA Grants Accelerated Approval To Day One's Ojemda (Tovorafenib) For Relapsed Or Refractory BRAF-Altered Pediatric Low-grade Glioma
Portfolio Pulse from Benzinga Newsdesk
Xoma Corporation has earned $9 million due to the FDA's accelerated approval of Day One's Ojemda (Tovorafenib) for treating relapsed or refractory BRAF-Altered Pediatric Low-grade Glioma. This milestone payment is a significant financial event for Xoma, highlighting the company's involvement in the development and success of Ojemda.
April 25, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xoma Corporation receives a $9 million milestone payment following the FDA's accelerated approval of Ojemda, marking a significant financial boost.
The $9 million milestone payment directly impacts Xoma's financials, likely leading to positive investor sentiment and potentially boosting the stock price in the short term. This event underscores Xoma's successful partnership and involvement in the development of a now FDA-approved treatment, highlighting the company's strategic investments and potential for future earnings from similar agreements.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100